Workflow
津药药业:2025一季报净利润0.58亿 同比下降0%

Financial Performance - The company's basic earnings per share (EPS) for Q1 2025 remained unchanged at 0.0530 CNY compared to Q1 2024, but decreased from 0.0620 CNY in Q1 2023 [1] - The net profit for Q1 2025 was 0.58 billion CNY, consistent with Q1 2024, but down from 0.67 billion CNY in Q1 2023 [1] - Operating revenue for Q1 2025 was 7.86 billion CNY, a decrease of 9.03% from 8.64 billion CNY in Q1 2024 and down from 9.91 billion CNY in Q1 2023 [1] - The return on equity (ROE) for Q1 2025 was 1.88%, a decline of 3.09% from 1.94% in Q1 2024 and down from 2.24% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 65,344.49 million shares, accounting for 59.85% of the circulating shares, with an increase of 210.31 million shares from the previous period [2] - Tianjin Pharmaceutical Group Co., Ltd. remains the largest shareholder with 55,453.01 million shares, representing 50.79% of total share capital, unchanged from the previous report [2] - Hong Kong Central Clearing Limited increased its holdings by 324.11 million shares to 1,893.56 million shares, now holding 1.73% of total share capital [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]